[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Galectin 3 - Pipeline Review, H2 2019

December 2019 | 82 pages | ID: G426FC569E42EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Galectin 3 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Galectin 3 - Pipeline Review, H2 2019'; Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 18 molecules.

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

The report 'Galectin 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 12 and 3 respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Cardiovascular, Respiratory, Undisclosed, Genito Urinary System And Sex Hormones, Immunology and Ophthalmology which include indications Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Pulmonary Fibrosis, Unspecified, Breast Cancer, Idiopathic Pulmonary Fibrosis, Myocardial Fibrosis, Arrhythmias, Atrial Fibrillation, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Metastatic Prostate Cancer, Myocardial Infarction, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Sarcomas, Skin Cancer and Venous (Vein) Thrombosis.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
  • The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
G3 Pharmaceuticals Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Glycomantra Inc
GlycoMimetics Inc
Immutics Inc
MandalMed Inc
Proteris Biotech Inc
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
belapectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-1211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1757 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protearin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFD-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Galectin Therapeutics phase 2 NASH cirrhosis clinical trial results on belapectin (GR-MD-02) published in gastroenterology
Dec 05, 2019: Galectin Therapeutics plans adaptively designed phase 3 NASH-RX clinical trial in NASH Cirrhosis
Nov 11, 2019: Galectin Therapeutics reaches agreement with Siemens Healthineers to collaborate on NASH and Liver Fibrosis
Nov 05, 2019: Additional Ad Hoc analysis of ELF data from Galectin Therapeutics NASH-CX phase 2 clinical trial to be highlighted in poster presentation at the 2019 AASLD Liver Meeting
Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Aug 05, 2019: Galectin Therapeutics submits phase 3 NASH-RX protocol in Nash Cirrhosis to FDA
Mar 22, 2019: Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Dec 04, 2018: GlycoMimetics presents poster at 60th ASH Annual Meeting highlighting preclinical data on GMI-1757
Nov 05, 2018: Data collected by Exalenz Bioscience in Galectin Therapeutics phase 2 NASH-CX trial of GR-MD-02 to be presented at AASLD Annual Meeting
Sep 20, 2018: Galectin Therapeutics announces positive preliminary results from phase 1b clinical trial of GR-MD-02 and KEYTRUDA in advanced melanoma and expansion of the Trial
Jul 18, 2018: GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
Jun 27, 2018: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Jun 12, 2018: Galectin Therapeutics Announces New CEO
Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board
May 21, 2018: Galecto Biotech Strengthens Executive Team with Appointment of Richard Marshall as Chief Medical Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by G3 Pharmaceuticals Inc, H2 2019
Pipeline by Galectin Therapeutics Inc, H2 2019
Pipeline by Galecto Biotech AB, H2 2019
Pipeline by Glycomantra Inc, H2 2019
Pipeline by GlycoMimetics Inc, H2 2019
Pipeline by Immutics Inc, H2 2019
Pipeline by MandalMed Inc, H2 2019
Pipeline by Proteris Biotech Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

G3 Pharmaceuticals Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Glycomantra Inc
GlycoMimetics Inc
Immutics Inc
MandalMed Inc
Proteris Biotech Inc


More Publications